Postmarketing Safety Signals and Medication-Use Risks of GLP-1-Based Therapies in Diabetes and Obesity: A Multi-Source Pharmacovigilance and Regulatory Evidence-Mapping Study.
This study maps safety signals for GLP-1 therapies like exenatide but does not estimate incidence or causality. It's a tool for prioritizing safety concerns, not for clinical risk assessment.
Where it sits
this study against the rest of the exenatide corpusSummary and findings
The study analyzed postmarketing safety signals and medication-use risks of GLP-1 receptor agonists, including exenatide, using pharmacovigilance data. It utilized FAERS data from 2021 to 2026, focusing on primary-suspect case-product records. The analysis highlighted gastrointestinal intolerance and other medication-use events but did not estimate incidence or causality.
Abstract
<h4>Aims</h4>To characterise postmarketing safety signals and medication-use risks associated with GLP-1 receptor agonists and the GIP/GLP-1 co-agonist tirzepatide in diabetes and obesity care using an integrated pharmacovigilance, utilisation-context, regulatory, and external-consistency framework.<h4>Materials and methods</h4>FDA Adverse Event Reporting System (FAERS) data from 2021Q1 through 2026Q1 were processed using deleted-case exclusion, latest-case-version retention, and case-product deduplication with analysis at the GLP-1 primary-suspect case-product level. Primary-suspect records for semaglutide, tirzepatide, dulaglutide, liraglutide, exenatide, and lixisenatide were analysed using reporting odds ratios, proportional reporting ratios, and an approximate Information Component. Medicaid utilisation data, FDA labelling/Safety-Related Labelling Changes resources, FDA shortage and compounded-product communications, and Canada Vigilance reports provided contextual interpretation; no data source was used to estimate incidence, comparative risk, or causality.<h4>Results</h4>The final FAERS analysis set included 243 114 GLP-1 primary-suspect case-product records within 8 995 547 background reports. Tirzepatide accounted for 133 100 records, followed by semaglutide (55619) and dulaglutide (38406). Frequently reported terms included incorrect dose administered, nausea, injection-site pain, diarrhoea, vomiting, off-label use, and extra dose administered. Prioritised domains included gastrointestinal intolerance, medication-use/device events, impaired gastric emptying, pancreatobiliary events, renal/dehydration events, and hypoglycaemia. Canada Vigilance and FDA labelling/SrLC mapping showed descriptive visibility for most major domains, while medication-use terms reflected use-process rather than conventional adverse-drug-reaction issues.<h4>Conclusions</h4>Multi-source pharmacovigilance can improve interpretation of GLP-1 postmarketing safety evidence in diabetes and obesity care. Findings should be interpreted as signal-prioritisation and medication-safety evidence, not as incidence, proof of causality, or population-level comparative risk, given the limited clinical interpretability of spontaneous-reporting data.
Background
This study addresses the safety and medication-use risks of GLP-1 receptor agonists, including exenatide, in the treatment of diabetes and obesity. Previous research has focused on the efficacy of these drugs, but postmarketing safety data are crucial for understanding real-world risks. The study is significant as it uses a multi-source pharmacovigilance approach to prioritize safety signals and medication-use issues.
Methods
The study utilized data from the FDA Adverse Event Reporting System (FAERS) from 2021Q1 to 2026Q1. It employed deleted-case exclusion, latest-case-version retention, and case-product deduplication. The analysis focused on primary-suspect case-product records for several GLP-1 receptor agonists, including exenatide. Reporting odds ratios, proportional reporting ratios, and an approximate Information Component were used for analysis.
Results
The analysis included 243,114 GLP-1 primary-suspect case-product records. Tirzepatide had the highest number of records at 133,100, followed by semaglutide and dulaglutide. Commonly reported issues were gastrointestinal intolerance, medication-use/device events, and renal/dehydration events. The study did not estimate incidence or causality, focusing instead on signal prioritization.
Interpretation
The study provides a comprehensive overview of safety signals associated with GLP-1 receptor agonists but does not offer incidence or causality estimates. While the findings are statistically significant, their clinical significance is limited by the nature of the data. The results align with known side effects of GLP-1 therapies, but the lack of incidence data limits their applicability in clinical decision-making.
Key findings
- 243,114 GLP-1 primary-suspect case-product records analyzed.
- Tirzepatide accounted for 133,100 records.
- Frequently reported terms included nausea and injection-site pain.
- Prioritized domains included gastrointestinal intolerance and renal events.
- No incidence or causality estimation was performed.
Limitations
- No incidence or causality estimation.
- Relies on spontaneous-reporting data.
- Focuses on signal prioritization, not clinical outcomes.